Apyx Medical ((APYX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: The clinical study titled ‘Histological Evaluation of Human Skin Biopsies to Assess the Effects of Renuvion APR Treatment as an Adjunct Procedure in Facelift Surgery’ aims to evaluate the impact of the Renuvion device on skin quality. Conducted by Apyx Medical, the study focuses on measuring skin elasticity, hydration, and biological age through DNA methylation in participants undergoing lower facelift surgery.
Intervention/Treatment: The study tests the Renuvion APR System, a device designed to enhance skin quality by improving elasticity and hydration. It is used as an adjunct treatment during lower facelift surgeries.
Study Design: This is a prospective, single-arm study involving up to 10 participants. Conducted at three centers in the U.S., it features no masking and focuses on treatment. Participants receive standard lower facelift surgery followed by Renuvion treatment, with follow-ups extending to 180 days post-procedure.
Study Timeline: The study began on December 18, 2023, with its primary completion and last update noted on October 3, 2025. These dates are crucial for tracking progress and ensuring timely data collection and analysis.
Market Implications: The completion of this study could influence Apyx Medical’s stock performance positively, as successful results may boost investor confidence and market competitiveness. The Renuvion APR System’s potential to enhance facelift outcomes could position Apyx favorably against competitors in the cosmetic surgery market.
The study is completed, with further details available on the ClinicalTrials portal.